Latest News and Press Releases

MALVERN, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care...

ANJESO® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q4’20 Average Sales per Account Increased 30% in Q1 compared to Q4’20 Richard S....

MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings,...

Patients Administered ANJESO Prior to the Start of Surgery had Significantly Lower Summed Pain Intensity Scores on the First Postsurgical Day and Throughout Their Inpatient Course ANJESO Treated TKA...

MALVERN, Pa., April 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has...

MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation...

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood,...

MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard...

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood,...

Deepening Usage of ANJESO Evidenced by a Reorder Rate of 60% by the End of 2020 and 58% Growth in Vials Sold from the Sequential Quarter Secured Approximately $55 Million in Gross Proceeds from...